Fesperman Bart

SEC source: 0001261654-23-000092 · wk-form4_1695161145.xml · derivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.0001 par value · 3,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F4 · derivative.exercise_date: On September 15, 2020, the reporting person was granted restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On September 15, 2020, the reporting person was granted restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001261654-23-000092 · wk-form4_1695161145.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,067

F3 · shares: Shares withheld to satisfy tax liability for the vesting of restricted stock units granted on 9/15/2020.

SEC source: 0001261654-23-000092 · wk-form4_1695161145.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Commons Stock received from vesting of restricted stock units granted on 9/15/2020.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

SEC source: 0001261654-22-000171 · wf-form4_167096450285447.xml · derivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,646

Underlying: Common Stock, $0.0001 par value · 4,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on 12/10/2021.

F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on 12/10/2021.

SEC source: 0001261654-22-000171 · wf-form4_167096450285447.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,285

F3 · shares: Shares withheld to satisfy tax liability for the vesting of restricted stock units granted on 12/10/2020.

SEC source: 0001261654-22-000171 · wf-form4_167096450285447.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Common Stock received from vesting of restricted stock units granted on 12/10/2020.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

SEC source: 0001261654-22-000142 · wf-form4_167088808776191.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,083

Underlying: Common Stock, $0.0001 par value · 26,002 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2023.

SEC source: 0001261654-22-000142 · wf-form4_167088808776191.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,671

Underlying: Common Stock, $0.0001 par value · 39,194 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.expiration_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-22-000123 · wf-form4_167088233178482.xml · derivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,011

Underlying: Common Stock, $0.0001 par value · 4,505 shares

Expires 2024-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2022.

F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2022.

SEC source: 0001261654-22-000123 · wf-form4_167088233178482.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,896

F3 · shares: Shares withheld to satisfy tax liability for the vesting of restricted stock units granted on 12/08/2021.

SEC source: 0001261654-22-000123 · wf-form4_167088233178482.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Share of Common Stock received from vesting of restricted stock units granted on 12/08/2021.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

SEC source: 0001261654-23-000002 · wf-form4a_167339628513835.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,072

Underlying: Common Stock, $0.0001 par value · 25,991 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2023.

SEC source: 0001261654-23-000002 · wf-form4a_167339628513835.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,648

Underlying: Common Stock, $0.0001 par value · 39,171 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.expiration_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2025 and 40% of which vest based on adjusted EBITDA for the fiscal year ending September 30, 2025, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) immediately preceding and through grant date, and (ii) immediately preceding and through the 3rd anniversary of grant date (ending price). The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-22-000093 · wf-form4_166361857625046.xml · derivative · entry 4

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,778

Underlying: Common Stock, $0.0001 par value · 3,777 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F3 · derivative.exercise_date: On September 15, 2020, the reporting person was granted restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

F3 · derivative.expiration_date: On September 15, 2020, the reporting person was granted restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001261654-22-000093 · wf-form4_166361857625046.xml · nonDerivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,610

F2 · shares: Shares withheld to satisfy tax liability for the vesting of performance units granted on 9/15/2020.

SEC source: 0001261654-22-000093 · wf-form4_166361857625046.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,874

SEC source: 0001261654-22-000093 · wf-form4_166361857625046.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

SEC source: 0001261654-22-000014 · wf-form4_164254813227377.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.0001 par value · 975 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's Common Stock, $0.0001, 60% of which vested based on revenue and 40% of which vested based on income from operations for the fiscal year ending September 30, 2021, the sum of which was adjusted by a compound annual total shareholder return ("TSR") modifier. For purposes of determining the TSR, the change in the price of the Company's common stock was based upon the 30-trading day average closing stock price (i) ending on and including January 7, 2020, and (ii) ending on and including the last day of the Performance Period, or January 6, 2022. The number of shares delivered is equal to 8.6% performance achievement pursuant to the terms of the award and was approved by the Compensation Committee of the Board of Directors on January 13, 2022 per the terms of the award.

F1 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's Common Stock, $0.0001, 60% of which vested based on revenue and 40% of which vested based on income from operations for the fiscal year ending September 30, 2021, the sum of which was adjusted by a compound annual total shareholder return ("TSR") modifier. For purposes of determining the TSR, the change in the price of the Company's common stock was based upon the 30-trading day average closing stock price (i) ending on and including January 7, 2020, and (ii) ending on and including the last day of the Performance Period, or January 6, 2022. The number of shares delivered is equal to 8.6% performance achievement pursuant to the terms of the award and was approved by the Compensation Committee of the Board of Directors on January 13, 2022 per the terms of the award.

SEC source: 0001261654-22-000014 · wf-form4_164254813227377.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance unit represents a contingent right to receive one share of the Company's Common Stock, $0.0001, 60% of which vested based on revenue and 40% of which vested based on income from operations for the fiscal year ending September 30, 2021, the sum of which was adjusted by a compound annual total shareholder return ("TSR") modifier. For purposes of determining the TSR, the change in the price of the Company's common stock was based upon the 30-trading day average closing stock price (i) ending on and including January 7, 2020, and (ii) ending on and including the last day of the Performance Period, or January 6, 2022. The number of shares delivered is equal to 8.6% performance achievement pursuant to the terms of the award and was approved by the Compensation Committee of the Board of Directors on January 13, 2022 per the terms of the award.

SEC source: 0001261654-21-000103 · wf-form4_163978166457541.xml · derivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,292

Underlying: Common Stock, $0.0001 par value · 4,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on 12/10/2021.

F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on 12/10/2021.

SEC source: 0001261654-21-000103 · wf-form4_163978166457541.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,144

F3 · shares: Shares withheld to satisfy tax liability for the vesting of restricted stock units granted on 12/10/2020.

SEC source: 0001261654-21-000103 · wf-form4_163978166457541.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,401

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Common Stock received from vesting of restricted stock units granted on 12/10/2020.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

SEC source: 0001261654-21-000075 · wf-form4_163917377769712.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,009

Underlying: Common Stock, $0.0001 par value · 13,516 shares

Expires 2024-12-08

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on December 8, 2022.

SEC source: 0001261654-21-000075 · wf-form4_163917377769712.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,725

Underlying: Common Stock, $0.0001 par value · 25,343 shares

Expires 2024-12-08

F1 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2024 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2024, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2024 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2024, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-21-000065 · wf-form4_163217899284430.xml · derivative · entry 3

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,493

Underlying: Common Stock, $0.0001 par value · 3,777 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on 9/15/2021.

F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on 9/15/2021.

SEC source: 0001261654-21-000065 · wf-form4_163217899284430.xml · nonDerivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,755

F3 · shares: Shares withheld to satisfy tax liability for the vesting of restricted stock units granted on 9/15/2020.

SEC source: 0001261654-21-000065 · wf-form4_163217899284430.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of Common Stock received from vesting of restricted stock units granted on 9/15/2020.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock.

SEC source: 0001261654-20-000075 · wf-form4_160798845335007.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,270

Underlying: Common Stock, $0.0001 par value · 13,938 shares

Expires 2023-12-10

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on December 10, 2021.

SEC source: 0001261654-20-000075 · wf-form4_160798845335007.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,382

Underlying: Common Stock, $0.0001 par value · 26,134 shares

Expires 2023-12-10

F1 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2023 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2023, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F1 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the UTI Common Stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2023 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2023, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the UTI Common Stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-20-000053 · wf-form4_160037799600727.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,248

Underlying: Common Stock, $0.0001 par value · 21,248 shares

Expires 2022-09-15

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-20-000053 · wf-form4_160037799600727.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,332

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001261654-20-000093 · wf-form4a_160875875692799.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,270

Underlying: Common Stock, $0.0001 par value · 11,332 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F2 · shares: This Form 4/A does not report a new transaction. The reporting person's original Form 4 incorrectly reported these securities as Common Stock rather than restricted stock units.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F4 · balance_after: The incorrect classification described in footnote (2) above resulted in incorrect reporting of beneficial ownership of the UTI Common Stock in the original Form 4. As of the date of this Form 4/A, none of the restricted stock units has vested. The beneficial ownership of the restricted stock units has been corrected in this Form 4/A and reflects the reporting person's correct ownership as of the date of this filing.